Jun 16, 2022 / 01:00PM GMT
Dave Turkaly - JMP Securities - Analyst
Thank you for coming here today, Charlie, and we're kicking off day two. This is Charlie Goodwin from Apyx Medical, it's a company we've covered for a long time now since the prior management was there.
Questions and Answers:
Dave Turkaly - JMP Securities - AnalystSo I guess of late, you've had some good news and I think we start off with that so -- you got the first of your 510(k)s cleared on May 26. And that's what led us to reinstate a market outperform and with an $11 price target. And I think we certainly had thoughts, but I'd love to get yours as well -- sentiment, safety profile, and the specific label you got, just talk about what that means to you and how you think that might impact some of your other submissions?
Charlie Goodwin - Apyx Medical Corp. - CEO & Director
Yes. No. Thanks, Dave, and thanks for having us here. It was obviously a huge milestone for the company. It's something that we've been working on, quite frankly, for many years. One of the
Trustpilot
